LPT Pharm Tox (Hamburg, Germany) Partnered for Collaboration Agreement
- Created: 22 February 2012
Accelerō Bioanalytics GmbH, a GLP bioanalytical ligand binding assay service provider establishing an innovative business and marketing paradigm, announced today that it has entered into a collaboration agreement with LPT Laboratory of Pharmacology and Toxicology GmbH & Co KG (Hamburg, Germany).
This cooperation opens LPT the opportunity to access Accelerō Bioanalytics´ GLP compliant Real-Time qPCR assay portfolio. The recently acquired ViiA™ 7 qPCR system provides an ideal extension to LPT´s in-house bioanalytical services. As Accelerō Bioanalytics is one of the first to offer Real-Time qPCR assays in a regulatory context, this partnership now brings LPT into the position to offer a broader range of bioanalytical assays for its customers´ preclinical drug development pipelines.
Accelerō Bioanalytics in turn will promote LPT´s extensive pharmacological and toxicological service portfolio. According to the principle: “all from one hand”, this partnership prepares a beneficial complete preclinical drug development line from in vivo research to concomitant PK/PD bioanalysis.
LPT Laboratory of Pharmacology and Toxicology GmbH & Co KG is one of Germany’s leading GLP-accredited laboratories dedicated to toxicity testing. LPT´s experience spans over fifty years and several thousand studies. LPT’s strengths are in the areas of regulatory pre-clinical toxicology studies and safety assessment of chemicals. The company serves clients in the pharmaceutical, biotechnology, chemical and agrochemical sectors as well as contract research organizations and academic institutions. LPT is an independent company established in 1960. LPT employs experienced technicians, office, and auxiliary staff and operate from a modern, 10,000 square meter facility in the north of Germany, approx. 40 minutes from Hamburg airport.
Accelero Bioanalytics GmbH was established in September 2011 right in the heart of Europe. A complete new business and marketing model opens the possibility to offer pharmacokinetic and pharmakodynamic ligand binding assays under Good Laboratory Practice (GLP). Accelero Bioanalytics encounters the increasing need for validated ligand binding assays enabling ultra-sensitive bioanalysis of low sample volumes. You are welcome to visit also our XING presentation for more details on our services.
Accelero Bioanalytics is determined to become a preferred partner for the Biotech and Pharma business in the field of investigative new drugs based on nucleic acid chemistry.